Please login to the form below
lung cancer
This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
The HER-Vaxx jab is a B-cell activating cancer immunotherapy designed to target tumours that overexpress the HER2/neu receptor in gastric, breast, ovarian, lung and pancreatic cancers. ... Elsewhere in Imugene’s pipeline are a phase 1 triple negative
Latest news
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Expression of these genetic defects is often associated with rare cancer subtypes in which patients have few therapeutic options available to them. ... NTRK alterations generally have low expression in more common cancer types such as lung and breast
-
AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China
The NMPA has granted Orpathys ( savolitinib) a conditional approval for the treatment of patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations, who have progressed following ... This approval makes Orpathys the only
-
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer,” he added. ... the treatment of patients with metastatic non-small cell lung
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. ... study. In a statement, AZ said that approximately a fifth of global
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung cancer (NSCLC).
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
More from news
Approximately 111 fully matching, plus 854 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced non-small-cell lung cancer by four to five
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
The promise of precision medicine
Successful product commercialisation: what can we learn from the rare disease setting?
Growing evidence supports the important role of biosimilars in healthcare
Unlocking the potential of precision medicine in oncology
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
More from intelligence
Approximately 1 fully matching, plus 62 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
-
Iris Pauporté joins OSE Immunotherapeutics
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
-
Merck appoints ex-Pfizer exec as global head of oncology
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Astellas bolsters oncology clinical development leadership
Iris Pauporté joins OSE Immunotherapeutics
Astellas promotes John Demaree
Merck appoints ex-Pfizer exec as global head of oncology
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
-
September 2020: diversity and inclusion in clinical trials round-up
The Hispanic population is underrepresented in lung cancer trials despite experiencing different health outcomes to white people. ... The Hispanic population is generally not represented in lung cancer trials because of limited access and few research
-
July 2020: diversity and inclusion in clinical trials round-up
Black people are among those who typically suffer poorer health outcomes from lung cancer. ... Early next year, a Stand Up To Cancer Innovation Summit will launch the project, which will bring together lung cancer experts with researchers specializing in
-
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. ... 2017 Jul 11; 318(2):197-198. Denis F, Basch E et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine
September 2020: diversity and inclusion in clinical trials round-up
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital project manager
-
Competitive
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital strategist
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
Latest intelligence
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
